Format

Send to

Choose Destination
J Gastroenterol. 2018 Sep 19. doi: 10.1007/s00535-018-1509-4. [Epub ahead of print]

The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin.

Author information

1
Department of Internal Medicine, Gastroenterology Unit, Policlinico "San Martino", University of Genoa, Viale Benedetto XV, 6, 16132, Genoa, Italy. manuelefurnari@gmail.com.
2
Cystic Fibrosis Center, IRCCS G. Gaslini Institute, Genoa, Italy.
3
Gastroenterology and Pediatric Endoscopy Unit, IRCCS G. Gaslini Institute, Genoa, Italy.
4
Epidemiology and Biostatistic Service, IRCCS G. Gaslini Institute, Genoa, Italy.
5
Department of Internal Medicine, Gastroenterology Unit, Policlinico "San Martino", University of Genoa, Viale Benedetto XV, 6, 16132, Genoa, Italy.
6
Department of Gastroenterology, Aldara Hospital and Medical Centre, Riyadh, Kingdom of Saudi Arabia.

Abstract

BACKGROUND:

Scientific literature shows a high prevalence of Small Intestinal Bacterial Overgrowth (SIBO) in patients with Cystic Fibrosis (CF). The role of SIBO in nutritional status and gastrointestinal symptoms in CF is not known. Our aim was to study epidemiology and clinical impact of SIBO while assessing the efficacy of rifaximin in eradicating SIBO in CF patients.

METHODS:

Symptoms questionnaire and Glucose Breath Test (GBT) were given to 79 CF patients (median age 19.6 years; 9.2-36.9). Subjects with a positive GBT were enrolled in a randomized controlled trial and received rifaximin 1200 mg for 14 days or no treatment. Questionnaire and GBT were repeated 1 month after the end of treatment or 45 days after the first negative GBT.

RESULTS:

Out of 79 patients, 25 were affected by SIBO (31.6%) with a significant correlation with lower BMI, SDS-BMI (p < 0.05) and serum albumin levels (p < 0.05), independently from pancreas insufficiency. Twenty-three patients took part in the randomized trial, 13 patients (56.5%) in rifaximin group and 10 patients (43.5%) in control group. Eradication rate of SIBO was 9/10 (90%) in rifaximin group and 2/6 (33.3%) in control group (p < 0.05). In the rifaximin group, gastrointestinal symptom improvement was observed in 4/5 patients aged ≤ 14 years and in 0/5 patients aged > 14 years (p < 0.05); in 2/6 patients in the control group.

CONCLUSIONS:

CF patients show a high prevalence of SIBO, related to a poorer nutritional status. Rifaximin therapy is well tolerated and the results are promising in terms of efficacy in eradicating small intestinal bacterial overgrowth in CF.

KEYWORDS:

Cystic fibrosis; Hypoalbuminemia; Malabsorption; Malnutrition; Rifaximin; Small intestinal bacterial overgrowth

PMID:
30232597
DOI:
10.1007/s00535-018-1509-4

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center